Thermo Fisher Scientific Inc.
NYSE:TMOMedical - Diagnostics & Research
+$4.45 today
- Market cap
- $256.67B
- Beta
- 0.87
- P/E (TTM)
- 25.3
- EPS (TTM)
- $18.44
- Dividend yield
- 0.39%
Volume 1.99M
Average 2.23M
TMO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Thermo Fisher Scientific Inc.NYSE: TMO
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization remains negative
Q3 FY2026 depreciation & amortization was $0, compared with $661M a year earlier. Trailing-twelve-month depreciation & amortization was $2.28B. Over 3 fiscal years it compounded at -6.3% a year.
Context
- Depreciation & amortization amounted to 6.2% of revenue in FY2025, down 1.0 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $570.25M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.78B USD
- Year-over-year change
- -10.6%
- 4-year CAGR
- +1.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.78B | -10.6% |
| FY2024 | 2024-12-31 | 3.11B | -8.7% |
| FY2023 | 2023-12-31 | 3.41B | +0.7% |
| FY2022 | 2022-12-31 | 3.38B | +30.4% |
| FY2021 | 2021-12-31 | 2.59B | — |
Depreciation & Amortization vs competitors
How TMO compares with its peers on the latest reported figures
- TMO's LTM Sep 2026 depreciation & amortization of $2.28B is the highest of the 10 companies compared; the peer median is $230.1M.
- Its year-over-year change of -18.3% is the 8th highest of 10, against a peer median of -0.2%.
- Depreciation & amortization amounts to 4.8% of revenue for TMO, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.28B | -18.3% | -6.3% | 4.8% | |
| LTM Sep 2026 | $1.91B | -21.1% | +4.7% | 7.5% | |
| LTM Jul 2026 | $613.22M | +211.1% | +16.5% | 13.2% | |
| LTM Jul 2026 | $412.24M | -0.2% | -1.7% | 14.2% | |
| LTM Jul 2026 | $271M | -5.2% | -3.1% | 3.7% | |
| LTM Jun 2026 | $230.1M | +9.4% | +35.4% | 6.6% | |
| LTM Jun 2026 | $202.13M | +7.0% | -2.4% | 9.6% | |
| LTM Jun 2026 | $131M | +7.3% | +3.6% | 3.2% | |
| LTM Jun 2026 | $127.6M | -23.5% | +6.4% | 4.9% | |
| LTM Sep 2026 | $96.75M | -8.8% | -3.2% | 7.9% | |
| Peer median (excluding TMO) | $230.1M | -0.2% | +3.6% | 7.5% | |
Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B |
| Cost of Revenue | 19.58B | 25.9B | 25.66B | 25.15B | 26.32B |
| Gross Profit | 19.63B | 19.01B | 17.19B | 17.73B | 18.24B |
| Gross Margin | 50.1% | 42.3% | 40.1% | 41.3% | 40.9% |
| Research & Development | 1.41B | 1.47B | 1.34B | 1.39B | 1.4B |
| Selling, General & Admin | 7.91B | 9.02B | 8.41B | 8.68B | 8.73B |
| Operating Expenses | 9.32B | 10.49B | 9.75B | 10.07B | 10.13B |
| Depreciation & Amortization | 2.59B | 3.38B | 3.41B | 3.11B | 2.78B |
| EBITDA | 11.97B | 11.94B | 11.2B | 11.8B | 11.47B |
| EBITDA Margin | 30.5% | 26.6% | 26.1% | 27.5% | 25.7% |
| Operating Income | 10.32B | 8.53B | 7.45B | 7.66B | 8.11B |
| Operating Margin | 26.3% | 19.0% | 17.4% | 17.9% | 18.2% |
| Interest Income | 43M | 272M | 879M | 1.08B | 993M |
| Interest Expense | 536M | 726M | 1.49B | 1.65B | 1.42B |
| Other Income / Expenses | (1.48B) | (862M) | (1.21B) | (667M) | (842M) |
| Income Before Tax | 8.84B | 7.66B | 6.24B | 7B | 7.27B |
| Pre-Tax Margin | 22.5% | 17.1% | 14.6% | 16.3% | 16.3% |
| Income Tax Expense | 1.11B | 703M | 284M | 657M | 547M |
| Net Income | 7.73B | 6.95B | 6B | 6.34B | 6.74B |
| Net Margin | 19.7% | 15.5% | 14.0% | 14.8% | 15.1% |
| EPS (Basic) | 19.61 | 17.73 | 15.53 | 16.58 | 17.77 |
| EPS (Diluted) | 19.46 | 17.64 | 15.45 | 16.53 | 17.74 |
| Weighted Avg Shares | 394M | 392M | 386M | 382M | 376M |
| Weighted Avg Shares (Diluted) | 397M | 394M | 388M | 383M | 377M |
Thermo Fisher Scientific Inc.
NYSE:TMO
Intrinsic Alpha fair value
Locked
Current Price
$692.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.